The right choice of antihypertensives protects primary human hepatocytes from ethanol- and recombinant human TGF-β1-induced cellular damage

• Published in: Hepatic medicine: evidence and research Vol. 5; no. default; pp. 31 - 41
• Main Authors: Ehnert, Sabrina, Lukoschek, Teresa, Bachmann, Anastasia, Martínez Sánchez, Juan J, Damm, Georg, Nussler, Natascha C, Pscherer, Stefan, Stöckle, Ulrich, Dooley, Steven, Mueller, Sebastian, Nussler, Andreas K
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 2013; Dove Medical Press
• Subjects: Antihypertensives; Blood pressure; Ethanol; Hypertension; Liver diseases; Original Research; Reactive oxygen species; Transforming growth factor-b1; antihypertensives; TGF-β1; alcoholic liver disease; primary human hepatocytes; ethanol
• DOI: 10.2147/HMER.S38754
• EISSN: 1179-1535

Patients with alcoholic liver disease (ALD) often suffer from high blood pressure and rely on antihypertensive treatment. Certain antihypertensives may influence progression of chronic liver disease. Therefore, the aim of this study is to investigate the impact of the commonly used antihypertensives amlodipine, captopril, furosemide, metoprolol, propranolol, and spironolactone on alcohol-induced damage toward human hepatocytes (hHeps).
hHeps were isolated by collagenase perfusion. Reactive oxygen species (ROS) were measured by fluorescence-based assays. Cellular damage was determined by lactate-dehydrogenase (LDH)-leakage. Expression analysis was performed by reverse-transcription polymerase chain reaction and Western blot. Transforming growth factor (TGF)-β signaling was investigated by a Smad3/4-responsive luciferase-reporter assay.
Ethanol and TGF-β1 rapidly increased ROS in hHeps, causing a release of 40%-60% of total LDH after 72 hours. All antihypertensives dose dependently reduced ethanol-mediated oxidative stress and cellular damage. Similar results were observed for TGF-β1-dependent damage, except for furosemide, which had no effect. As a common mechanism, all antihypertensives increased heme-oxygenase-1 (HO-1) expression, and inhibition of HO-1 activity reversed the protective effect of the drugs. Interestingly, Smad3/4 signaling was reduced by all compounds except furosemide, which even enhanced this profibrotic signaling. This effect was mediated by expressional changes of Smad3 and/or Smad4.
Our results suggest that antihypertensives may both positively and negatively influence chronic liver disease progression. Therefore, we propose that in future patients with ALD and high blood pressure, they could benefit from an adjusted antihypertensive therapy with additional antifibrotic effects.